Qure.ai nets $65M for foundational AI
Qure.ai has raised $65 million in a Sequence D funding spherical led by Lightspeed and 360 ONE Asset.
The corporate stated it is going to use its contemporary funds to speculate extra in foundational AI fashions, in addition to purchase complementary startups in medical know-how. It’ll even be used to speed up its enlargement in america and different markets.
Early this yr, the Mumbai-based firm obtained two main clearances from america Meals and Drug Administration: a breakthrough machine designation for its tuberculosis screening AI resolution, qSpot-TB, and a 510(okay) clearance for the lung nodule on the qXR AI-powered chest X-ray software program.
Mediwhale luggage $12M to hunt US FDA approval
South Korean well being diagnostics agency Mediwhale has scored $12 million in a Sequence A2 funding spherical led by the Korea Improvement Financial institution.
The corporate claims to supply the world’s first retina-based resolution – referred to as Reti-CVD – that makes use of AI to evaluate heart problems threat.
It plans to make use of its new funds to pursue a US FDA approval for Reti-CVD. The software program was reportedly rolled out throughout the Yonsei College Well being System early this yr.
“We’re decided to safe FDA De Novo approval by 2025, with plans to launch our product in america shortly thereafter,” CEO Kevin Choi stated in an announcement.
Apart from securing a regulatory clearance, Mediwhale additionally seeks to enhance its AI additional and develop new options to foretell persistent kidney illness threat.
Mediwhale final raised $2 million in a pre-Sequence A funding spherical in 2021 and $9 million in a Sequence A spherical in 2023.
Huawei launches medical imaging AI
Huawei just lately unveiled a brand new AI-powered resolution for analysing medical photos.
Known as “Medical Know-how Digitalization 2.0,” the know-how allows good segmentation, detection, and quantitative evaluation of medical photos utilizing AI with as much as 98% accuracy. Huawei claims the answer can shorten illness prognosis time by 40%, though it has not specified which illness.
Moreover, the AI resolution will also be utilized to ultrasound units working on the OpenHarmony working system.
The Chinese language tech big labored with a number of native medical know-how firms, together with MED Imaging AI, Wanxiang, Beijing DeepWise, and KFBIO, to develop the answer, which has been applied in such main initiatives because the Fourth Individuals’s Hospital in Shenyang, capital of China’s northeast Liaoning Province.
Korean pharma turns to AI for new drug discovery
Korean pharmaceutical firm GI Innovation is pursuing the appliance of AI for brand new drug improvement.
It just lately signed a memorandum of understanding with native firm i-Divine to develop its core most cancers drug pipelines and utilise the latter’s AI resolution to find new most cancers remedy targets.
i-Divine’s AI relies on a big language mannequin skilled on over a billion patents, papers, and real-time organic information sourced globally. It was beforehand utilised to analyse the success potential of 16,000 new drug substances, together with one in every of GI Innovation’s anti-cancer drug pipelines.
MediBuddy adopts Philips’ predictive coronary heart AI
MediBuddy in India is integrating Philips’ coronary heart well being monitoring platform into its cellular well being software.
The AI-based longitudinal triaging resolution referred to as HeartPrint tracks and assesses key biomarkers from an individual’s finger when scanned by way of their smartphone’s digital camera. These embrace cardiovascular age, diabetes threat, OSA threat, cardio-respiratory health index, coronary heart price evaluation, cardiac index, blood strain variability, and stress dysfunction prediction.
The AI resolution additionally analyses patterns indicating an individual’s threat of creating coronary heart illness, general well being deterioration, coronary heart resilience, and quick and long-term adjustments in cardiac perform.
Add Comment